Currently Closed – We are no longer accepting or processing applications for new or renewal patients.
The PAN Foundation’s Tuberous Sclerosis Complex fund is currently closed. As of February 24, 2020, the National Organization for Rare Disorders is accepting applications.
For current information, log in to FundFinder.
$3,100 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.
- The patient must be getting treatment for tuberous sclerosis complex.
- The patient must have health insurance that covers his or her qualifying medication or product.
- The patient’s medication or product must be listed on PAN’s list of covered medications.
- The patient’s income must fall at or below 500% of the Federal Poverty Level.
- The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
See the list of medications covered in this program
- Acthar (corticotropin)
- Afinitor (everolimus)
- Everolimus (everolimus)
- Hydrocortisone (hydrocortisone)
- Medrol (methylprednisolone)
- Methylprednisolone (methylprednisolone)
- Prednisone (prednisone)
- Rapamune (sirolimus)
- Sabril (vigabatrin)
- Sirolimus (sirolimus)
- Vigabatrin (vigabatrin)
- Vigadrone (vigabatrin)
- Zortress (everolimus)
About the Disease:
Tuberous sclerosis complex (TSC) is a genetic disease that causes noncancerous tumors to grow in many parts of the body. TSC is a rare disease that affects the nervous system.
Source: National Institutes of Health